be steady state commonly referred to as u201c timed release u201d or zero order kinetics that is the drug is release in even amounts over a predetermined time with or without an initial burst phase or may be a gradient release a gradient release implies that the concentration of drug released from the device surface changes over time controlling drug release rates from the polymers of the drug polymer coating of the present disclosure requires adjusting the properties of the polymers one non limiting method of controlling drug release rates in the polymers of the present disclosure involves controlling the glass transition temperature tg of the polymers as used herein glass transition temperature tg refers to a temperature wherein a polymer structurally transitions from an elastic pliable state to a rigid and brittle state in accordance with the scope and teachings of the present disclosure bioabsorbable polymers of the drug polymer bioabsorbable coatings of the present implantable device may be for example selected from the group consisting of polyesters such as polylactide poylglycolide polycaprolactone and their copolymers modified derivatives of caprolactone polymers polytrimethylene carbonate and polysaccharides polyethylene glycol hydrogels photo curable hydrogels terminal diols and combinations thereof the bioabsorbable polymer of the drug polymer bioabsorbable coating has a molecular weight that is greater than the molecular weight of the bioabsorbable primer polymer the bioabsorbable polymer of the drug polymer bioabsorbabe coating thus has greater mechanical strength than the instant bioabsorbable primer polymers due in part to it 39 s higher molecular.